Moderna announces first participant dosed in phase 2 study of omicron-specific bivalent booster candidate

Moderna's omicron-specific bivalent booster candidate (mrna-1273.214) combines moderna's omicron-specific booster candidate (mrna-1273.529) and the moderna covid-19 vaccine (mrna-1273) moderna expects to enroll approximately 375 participants in the u.s. cambridge, ma / accesswire / march 10, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that the first participant has been dosed in the phase 2 study of the company's omicron-specific bivalent booster candidate (mrna-1273.214), which combines moderna's omicron-specific booster candidate (mrna-1273.529) and the moderna covid-19 vaccine (mrna-1273). "we are pleased to begin this study of our bivalent booster candidate that includes our omicron-specific candidate and the moderna covid-19 vaccine.
MRNA Ratings Summary
MRNA Quant Ranking